Lv31
285 积分 2021-08-20 加入
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
3小时前
已完结
OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
4小时前
已完结
Zoldonrasib Deemed Safe, Effective in KRAS G12D-mutant NSCLC
3天前
求助中
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
1个月前
已完结
“The RAS Dam Has Broken”
1个月前
已完结
An overview of KRAS G12D inhibitors: Expanding the therapeutic frontier of KRAS in targeting KRAS G12D using diverse therapeutic modalities
1个月前
已完结
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
1个月前
已完结
“The RAS Dam Has Broken”
1个月前
已完结
Recent advances in therapeutic targeting of the KRAS pathway in cancer
1个月前
已完结
Emerging landscape of KRAS inhibitors in cancer treatment
1个月前
已完结
皖公网安备34019202002308
